Innovative TechnologyNXL is focused on revolutionizing the treatment of a wide range of mental health conditions using the company's proprietary transcranial alternating current stimulation (tACS) technology.

Market PotentialAs the first potential at-home tACS treatment for mental health, NXL could gain a first-mover advantage and set the standard for the market.

Regulatory ApprovalNXL has received approval from the FDA for pilot trial designs for the treatment of insomnia with its Gen-3 device.

Bears Say

Financial PerformanceThe GAAP net loss per share was significantly wider than estimates due to an increase in stock-based compensation.

Investment AdviceAnalysts advise investors not to purchase additional shares at this time as they believe the risk/reward is balanced.

Stock RatingThe share price has surpassed the previous price target, leading analysts to downgrade the stock rating from Buy to Hold as they view it as fairly valued.

---

Financials

Annual

Income Statement >

Ownership Overview

15.59% Insiders

0.56% Mutual Funds

0.18% Other Institutional Investors

82.73% Public Companies and Individual Investors

Detailed Ownership Overview >

Risk Analysis

Main Risk Category

Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Detailed Risk Analysis >

NXL FAQ

What was Nexalin Technology, Inc.’s price range in the past 12 months?

Nexalin Technology, Inc. lowest stock price was $0.25 and its highest was $4.49 in the past 12 months.

What is Nexalin Technology, Inc.’s market cap?

Nexalin Technology, Inc.’s market cap is $42.04M.

When is Nexalin Technology, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nexalin Technology, Inc.’s earnings last quarter?

Currently, no data Available

Is Nexalin Technology, Inc. overvalued?

According to Wall Street analysts Nexalin Technology, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nexalin Technology, Inc. pay dividends?

Nexalin Technology, Inc. does not currently pay dividends.

What is Nexalin Technology, Inc.’s EPS estimate?

Nexalin Technology, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nexalin Technology, Inc. have?

Nexalin Technology, Inc. has 13,303,523 shares outstanding.

What happened to Nexalin Technology, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nexalin Technology, Inc.?

Currently, no hedge funds are holding shares in NXL

---

Nexalin Technology, Inc. Stock Smart Score

Unlock Smart Score

Fundamentals

Return on Equity

-135.57%

Trailing 12-Months

Asset Growth

18.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nexalin Technology, Inc.

Nexalin Technology Inc design and develop innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy.

---